[HTML][HTML] BRAF gene and melanoma: Back to the future

M Ottaviano, EF Giunta, M Tortora, M Curvietto… - International Journal of …, 2021 - mdpi.com
As widely acknowledged, 40–50% of all melanoma patients harbour an activating BRAF
mutation (mostly BRAF V600E). The identification of the RAS–RAF–MEK–ERK (MAP kinase) …

[HTML][HTML] Immune checkpoint inhibitors in hepatocellular carcinoma: current status and novel perspectives

P Federico, A Petrillo, P Giordano, D Bosso… - Cancers, 2020 - mdpi.com
Simple Summary Immune checkpoint inhibitors represent a promising treatment choice in
many kind of tumours, including hepatocellular carcinoma (HCC). In this review, we provide …

Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma

M Ottaviano, S De Placido, PA Ascierto - Virchows Archiv, 2019 - Springer
Several researches have been carried over the last few decades to understand of how
cancer evades the immune system and thus to identify therapies that could directly act on …

[PDF][PDF] Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy

PA Zucali, T De Pas, G Palmieri… - Journal of Clinical …, 2018 - researchgate.net
Purpose No effective salvage treatments are available for patients with advanced/recurrent
thymoma (T) or thymic carcinoma (TC) who have progressed after platinum-based …

[HTML][HTML] Distribution of mediastinal lesions across multi-institutional, international, radiology databases

AC Roden, W Fang, Y Shen, BW Carter… - Journal of Thoracic …, 2020 - Elsevier
Introduction Mediastinal lesions are uncommon; studies on their distribution are, in general,
small and from a single institution. Furthermore, these studies are usually based on …

[HTML][HTML] Epigenetic regulation in melanoma: facts and hopes

EF Giunta, G Arrichiello, M Curvietto, A Pappalardo… - Cells, 2021 - mdpi.com
Cutaneous melanoma is a lethal disease, even when diagnosed in advanced stages.
Although recent progress in biology and treatment has dramatically improved survival rates …

Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)

M Imbimbo, M Ottaviano, M Vitali, A Fabbri… - Cancer Treatment …, 2018 - Elsevier
Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex
histopatological classification. Furthermore, the recent introduction of the first TNM staging …

[HTML][HTML] Anorectal and genital mucosal melanoma: diagnostic challenges, current knowledge and therapeutic opportunities of rare melanomas

M Ottaviano, EF Giunta, L Marandino, M Tortora… - Biomedicines, 2022 - mdpi.com
Mucosal melanomas (MM) are rare tumors, being less than 2% of all diagnosed melanomas,
comprising a variegated group of malignancies arising from melanocytes in virtually all …

[HTML][HTML] CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

D Mallardo, M Fordellone, A White, M Ottaviano… - Journal of Translational …, 2023 - Springer
Background Identifying response markers is highly needed to guide the treatment strategy in
patients with metastatic melanoma. Methods A retrospective study was carried out in …

[HTML][HTML] Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response

G Cernera, M Gelzo, P De Placido… - Frontiers in …, 2023 - frontiersin.org
Background Thymic epithelial tumors (TETs) are rare malignancies with heterogeneous
clinical manifestations. The high frequency of autoimmune paraneoplastic disorders …